Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tea tree oil 5% gel
- Development stage
- Unknown
- Lead developer
- University of Alexandria
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
A 5% tea tree oil (Melaleuca alternifolia) gel formulation developed by Alexandria University for the treatment of stage 2 (moderate) periodontitis. It is designed for intrapocket application as an adjunctive therapy to scaling and root planing (SRP). The formulation utilizes Carbopol 940 as a gelling agent and exhibits broad-spectrum antimicrobial, anti-inflammatory, antifungal, antiviral, and antioxidant properties. Clinical studies have demonstrated its efficacy in improving clinical parameters and reducing biochemical markers such as matrix metalloproteinase-8 (MMP-8) in gingival crevicular fluid.
- Other names
- TTO geltea tree oil gel
Beyond the preview
Go deeper on tea tree oil 5% gel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tea tree oil 5% gel.